DE2463143C2 - Polyvalente Rindervirus-Lebendimpfstoffe - Google Patents
Polyvalente Rindervirus-LebendimpfstoffeInfo
- Publication number
- DE2463143C2 DE2463143C2 DE2463143A DE2463143A DE2463143C2 DE 2463143 C2 DE2463143 C2 DE 2463143C2 DE 2463143 A DE2463143 A DE 2463143A DE 2463143 A DE2463143 A DE 2463143A DE 2463143 C2 DE2463143 C2 DE 2463143C2
- Authority
- DE
- Germany
- Prior art keywords
- virus
- live
- bovine
- temperature
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
- C12N2710/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/813—Viral vaccine for bovine species, e.g. cattle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/821—Drug, bio-affecting and body treating compositions involving temperature-sensitive mutant virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Zur Herstellung der nlcht-pathogenen Mutantenstämme, wird entweder ein Rlnder-Adeno-Vlrusstamm. wie
Der Eunlce-Stamm wird In primären foetalen Rindernieren (PFBK)-Zellkulturen bei 30 bis 350C passagiert. Die In Tabelle II zusammengefaßten Ergebnisse zeigen, daß der «-Charakter während 7 Passagen bei 30 bis 350C stabil bleibt, während das Wachstum des Stammes bei 39,5° C beträchtlich vermindert Ist.
Passage | Virusliter TCID56, | ml | bei 39,5° C |
ausgedrückt in Ioglo/0,l | 0.5 | ||
bei 3O-35°C | 1.5 | ||
I | 5 | 1,5 | |
4 | 6,25 | ||
7 | 6,3 | ||
Serologische | 24 | nach der Impfung |
63 143 | nach der Impfung |
Haemagglulinations- Hemmungstiter für |
nach der Impfung |
I | |
Tabelle IV | 16 | 2 | Plj-Virus | 128 | 1 | |||
Nummer | Reaktion, ausgedrückt | 32 | in | 2 | vor der Impfung |
32 | !"* | |
des Tieres 5 |
Seroneutralisations-Antikörpertiter | 32 | ur | 8 | < 8 | 128 | Πι | |
Adeno-3-Virus | 64 | IBR-Virus | 1 | 8 | 32 | I | ||
vor der Impfung |
vor der Impfung |
< 8 | f. | |||||
O 1 |
< 4 | 0 | 32 | |||||
2 | <16 | 0 | I | |||||
3 | < 4 | 0 | I * |
|||||
5 4 | 8 | 0 | ||||||
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36021973A | 1973-05-14 | 1973-05-14 | |
US05438503 US3927208A (en) | 1973-05-14 | 1974-01-31 | Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them |
Publications (1)
Publication Number | Publication Date |
---|---|
DE2463143C2 true DE2463143C2 (de) | 1985-04-11 |
Family
ID=27000811
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2463143A Expired DE2463143C2 (de) | 1973-05-14 | 1974-05-13 | Polyvalente Rindervirus-Lebendimpfstoffe |
DE2423129A Expired DE2423129C2 (de) | 1973-05-14 | 1974-05-13 | Temperaturempfindliche, nicht-pathogene Rinder-Adeno-Virus-Mutantenstämme, Verfahren zu ihrer Herstellung und diese Virusstämme enthaltender Lebendimpfstoff |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2423129A Expired DE2423129C2 (de) | 1973-05-14 | 1974-05-13 | Temperaturempfindliche, nicht-pathogene Rinder-Adeno-Virus-Mutantenstämme, Verfahren zu ihrer Herstellung und diese Virusstämme enthaltender Lebendimpfstoff |
Country Status (13)
Country | Link |
---|---|
US (1) | US3927208A (de) |
JP (1) | JPS5710845B2 (de) |
AR (1) | AR203646A1 (de) |
CA (1) | CA1039186A (de) |
CH (1) | CH589141A5 (de) |
DD (1) | DD112663A5 (de) |
DE (2) | DE2463143C2 (de) |
ES (1) | ES426215A1 (de) |
FR (1) | FR2229398B1 (de) |
GB (1) | GB1430711A (de) |
HU (1) | HU169758B (de) |
IE (1) | IE40924B1 (de) |
NL (1) | NL7406407A (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4225582A (en) * | 1979-03-08 | 1980-09-30 | The University Of Illinois Foundation | Vaccine for equine rhinopneumonitis |
US4618493A (en) * | 1982-10-13 | 1986-10-21 | Smithkline-Rit | Temperature sensitive strains of bovine viral diarrhoea virus, preparation thereof and vaccines containing them |
NZ224422A (en) * | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
US4867975A (en) * | 1988-01-27 | 1989-09-19 | University Of Delaware | Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof |
US6398774B1 (en) | 1999-09-29 | 2002-06-04 | Heska Corporation | Intranasal delivery system |
US7678087B2 (en) * | 1999-09-29 | 2010-03-16 | Heska Corporation | Equine intranasal delivery system |
WO2011121301A1 (en) | 2010-03-31 | 2011-10-06 | Stabilitech Ltd | Excipients for stabilising viral particles, polypeptides or biological material |
EP2552410B1 (de) | 2010-03-31 | 2018-10-24 | Stabilitech Biopharma Ltd | Verfahren zur konservierung von alaun-adjuvantien und imfpstoffe mit alaun-adjuvantien |
HUE026885T2 (en) | 2010-03-31 | 2016-08-29 | Stabilitech Ltd | Stabilize virus fragments |
GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
US10581081B1 (en) * | 2019-02-01 | 2020-03-03 | Chang Chun Petrochemical Co., Ltd. | Copper foil for negative electrode current collector of lithium ion secondary battery |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3052606A (en) * | 1958-08-30 | 1962-09-04 | Behringwerke Ag | Viral mutation with nitrites |
-
1974
- 1974-01-31 US US05438503 patent/US3927208A/en not_active Expired - Lifetime
- 1974-04-24 FR FR7414220A patent/FR2229398B1/fr not_active Expired
- 1974-04-25 CH CH570074A patent/CH589141A5/xx not_active IP Right Cessation
- 1974-05-10 IE IE1001/74A patent/IE40924B1/xx unknown
- 1974-05-11 ES ES426215A patent/ES426215A1/es not_active Expired
- 1974-05-13 DE DE2463143A patent/DE2463143C2/de not_active Expired
- 1974-05-13 CA CA199,628A patent/CA1039186A/en not_active Expired
- 1974-05-13 JP JP5376774A patent/JPS5710845B2/ja not_active Expired
- 1974-05-13 NL NL7406407A patent/NL7406407A/xx not_active Application Discontinuation
- 1974-05-13 DE DE2423129A patent/DE2423129C2/de not_active Expired
- 1974-05-14 GB GB2124874A patent/GB1430711A/en not_active Expired
- 1974-05-14 DD DD17849674A patent/DD112663A5/xx unknown
- 1974-05-14 AR AR25373674A patent/AR203646A1/es active
- 1974-05-14 HU HURE000551 patent/HU169758B/hu unknown
Non-Patent Citations (1)
Title |
---|
Mayr et. al: Virologische Arbeitsmethoden, Stuttgart 1974, S.263 u. 266 * |
Also Published As
Publication number | Publication date |
---|---|
GB1430711A (en) | 1976-04-07 |
JPS5710845B2 (de) | 1982-03-01 |
DD112663A5 (de) | 1975-04-20 |
DE2423129A1 (de) | 1974-12-05 |
HU169758B (de) | 1977-02-28 |
NL7406407A (de) | 1974-11-18 |
JPS5052226A (de) | 1975-05-09 |
CH589141A5 (de) | 1977-06-30 |
AR203646A1 (es) | 1975-09-30 |
IE40924L (en) | 1974-11-14 |
FR2229398A1 (de) | 1974-12-13 |
IE40924B1 (en) | 1979-09-12 |
FR2229398B1 (de) | 1978-03-24 |
DE2423129C2 (de) | 1985-01-10 |
US3927208A (en) | 1975-12-16 |
AU6888474A (en) | 1975-11-13 |
ES426215A1 (es) | 1976-11-16 |
CA1039186A (en) | 1978-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT407958B (de) | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation | |
DE2463143C2 (de) | Polyvalente Rindervirus-Lebendimpfstoffe | |
DE19612967A1 (de) | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren | |
DE19612966A1 (de) | Tierische Zellen und Verfahren zur Vermehrung von Influenzaviren | |
EP1427817A1 (de) | Vermehrung von viren in zellkultur | |
EP1427815A2 (de) | Verfahren zur herstellung eines aktiven bestandteils eines arznei- oder diagnosemittels in mdck-zell-suspensionskultur | |
DE69923470T2 (de) | Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion | |
DE2708668A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
DE1617940C2 (de) | Verfahren zur Gewinnung eines für die Züchtung von Viren geeigneten Zellstammes | |
DE2362067C2 (de) | Temperaturempfindliche, nicht-pathogene, infektiöse Rinder-Rhinotracheitis-Virusstämme, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Lebendimpfstoffen | |
DE2817891A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
EP0019218A2 (de) | Influenzavirus-Vaccine, Verfahren zu ihrer Herstellung und Verfahren zur Vermehrung von Influenzaviren | |
DE2323847C3 (de) | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion | |
DE2553998C2 (de) | Mumpsvaccin und Verfahren zu seiner Herstellung | |
DE1198489B (de) | Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie | |
DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
CH616959A5 (de) | ||
DE2415353C2 (de) | ||
CH618091A5 (en) | Method for the attenuation of virulent feline rhinotracheitis virus and use of this virus for the production of a vaccine | |
DE2225548A1 (de) | Intravenoes vertraegliche staupe- und hepatitisvaccine | |
EP0223915A2 (de) | Lebendimpfstoff gegen Mumps und Verfahren zu dessen Herstellung | |
AT231068B (de) | Verfahren zur Herstellung von Vaccinzwischenprodukten | |
DE1021128B (de) | Verfahren zur Herstellung eines Impfstoffes gegen die Rhinotracheitis der Rinder | |
DE1138888B (de) | Verfahren zur Herstellung einer Vaccine gegen Staupe | |
AT234902B (de) | Verfahren zur Herstellung einer Vaccine gegen Staupe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AC | Divided out of |
Ref country code: DE Ref document number: 2423129 Format of ref document f/p: P |
|
Q172 | Divided out of (supplement): |
Ref country code: DE Ref document number: 2423129 |
|
8110 | Request for examination paragraph 44 | ||
8126 | Change of the secondary classification |
Free format text: A61K 39/295 A61K 39/265 A61K 39/155 C12N 7/06 |
|
AC | Divided out of |
Ref country code: DE Ref document number: 2423129 Format of ref document f/p: P |
|
D2 | Grant after examination | ||
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: SMITHKLINE BECKMAN - ANIMAL HEALTH PRODUCTS S.A., |
|
8328 | Change in the person/name/address of the agent |
Free format text: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT. RAUH, P., DIPL.-CHEM. DR.RER.NAT. HERMANN, G., DIPL.-PHYS. DR.RER.NAT. SCHMIDT, J., DIPL.-ING. JAENICHEN, H., DIPL.-BIOL. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN |